News Headlines Article

High cost of hepatitis drug reflects a broken pricing system
Los Angeles Times

Jane Blumenfeld isn’t sure when or how she contracted hepatitis C. All she knows is that back in 2000, when she tried to donate blood, the lab told her she had it.

After that she shared the nightmare of millions of hepatitis C victims.

Hoping to stave off the disease’s most dire outcomes — progressive liver damage, liver cancer or a liver transplant — she underwent what until recently was the preferred therapy.